Lithium Carbonate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lithium Carbonate: From No Registered Indication to Pseudoachondroplasia
One-Sentence Summary
Lithium carbonate (DrugBank DB14509) has no approved indication or licensed product on file in the available regulatory data, and detailed mechanism-of-action data is currently a gap. The TxGNN model’s top prediction for this drug is Pseudoachondroplasia, with a prediction score of 99.98%, but currently 0 clinical trials and 0 publications specifically support this candidate, and the underlying knowledge-graph signal may reflect score clustering rather than a disease-specific association.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication or marketing license on file |
| Predicted New Indication | Pseudoachondroplasia |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only, no clinical or literature evidence) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for lithium carbonate is not available in the current dataset (data gap DG002, severity: High), and no approved indication or license record exists in this jurisdiction (market status: Not Marketed, 0 licenses on file). This significantly limits mechanistic and regulatory context for evaluating the prediction.
The repurposing rationale attached to this candidate anchors the prediction on lithium’s known pharmacology as a GSK-3β inhibitor / Wnt pathway modulator. Pseudoachondroplasia is caused by COMP gene mutations leading to endoplasmic reticulum (ER) stress accumulation in chondrocytes. GSK-3/Wnt signaling is known to play a role in chondrocyte differentiation, but the evidence pack explicitly notes there is no direct literature link between this pathway and the ER-stress/protein-homeostasis mechanism underlying pseudoachondroplasia — the connection is inferential only.
Importantly, the evidence pack flags a specific caveat: within this prediction batch, multiple unrelated ultra-rare skeletal dysplasias received near-identical TxGNN scores (0.9998–0.9996), which raises the possibility that this is a knowledge-graph structural clustering artifact rather than a disease-specific signal. This should be weighed heavily when interpreting the score.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No marketing authorizations are on file for lithium carbonate in this jurisdiction — the drug is currently classified as Not Marketed, with 0 registered licenses.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are currently gaps — DG001, severity: Blocking, required before any S1 safety assessment can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by model score (L5) with no clinical trials or literature evidence, an inferential-only mechanistic link, and an explicit flag that the score may reflect knowledge-graph clustering across similar rare skeletal dysplasias rather than a true disease-specific signal.
To proceed, the following is needed:
- TFDA label warnings/contraindications (blocking gap, DG001)
- Confirmed mechanism-of-action data for lithium carbonate (DG002)
- Independent verification of whether the near-identical top-10 scores in this batch represent real signal or a structural artifact of the knowledge graph
- Disease-specific pharmacological or preclinical evidence linking GSK-3/Wnt modulation to COMP-related ER stress in pseudoachondroplasia
- Basic regulatory/indication data for lithium carbonate itself, since none is currently on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.